In Vitro Susceptibility Testing of Dientamoeba fragilis
Open Access
- 1 January 2012
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (1) , 487-494
Abstract
Dientamoeba fragilis is a commonly encountered trichomonad which has been implicated as a cause of gastrointestinal disease in humans. Despite the frequency of reports recording infections with this parasite, little research has been undertaken in terms of antimicrobial susceptibility. The aim of this study was to evaluate the susceptibility of D. fragilis to several commonly used antiparasitic agents: diloxanide furoate, furazolidone, iodoquinol, metronidazole, nitazoxanide, ornidazole, paromomycin, secnidazole, ronidazole, tetracycline, and tinidazole. Antibiotic susceptibility testing was performed on four clinical strains of D. fragilis , designated A, E, M, and V, respectively. Molecular testing followed, and all strains were determined to be genotype 1. The activities of antiprotozoal compounds at concentrations ranging from 2 μg/ml to 500 μg/ml were determined via cell counts of D. fragilis trophozoites grown in dixenic culture. Minimum lethal concentrations (MLCs) were as follows: ornidazole, 8 to 16 μg/ml; ronidazole, 8 to 16 μg/ml; tinidazole, 31 μg/ml; metronidazole, 31 μg/ml; secnidazole, 31 to 63 μg/ml; nitazoxanide, 63 μg/ml; tetracycline, 250 μg/ml; furazolidone, 250 to 500 μg/ml; iodoquinol, 500 μg/ml; paromomycin, 500 μg/ml; and diloxanide furoate, >500 μg/ml. This is the first study to report the profiles of susceptibility to a wide range of commonly used treatments for clinical isolates of D. fragilis . Our study indicated 5-nitroimidazole derivatives to be the most active compounds in vitro against D. fragilis .Keywords
This publication has 37 references indexed in Scilit:
- Newly defined conditions for thein vitrocultivation and cryopreservation ofDientamoeba fragilis: new techniques set to fast track molecular studies on this organismParasitology, 2010
- A Review of the Clinical Presentation of DientamoebiasisThe American Journal of Tropical Medicine and Hygiene, 2010
- Intragenomic Variation in the Internal Transcribed Spacer 1 Region of Dientamoeba fragilis as a Molecular Epidemiological MarkerJournal of Clinical Microbiology, 2008
- A comparison of metronidazole and single-dose ornidazole for the treatment of dientamoebiasisClinical Microbiology and Infection, 2008
- Determination of the In Vitro Susceptibility of Feline Tritrichomonas foetus to 5 Antimicrobial AgentsJournal of Veterinary Internal Medicine, 2007
- Tinidazole: A nitroimidazole antiprotozoal agentClinical Therapeutics, 2005
- Detection of Dientamoeba fragilis in fresh stool specimens using PCRInternational Journal for Parasitology, 2005
- Direct Amplification and Genotyping of Dientamoeba fragilis from Human Stool SpecimensJournal of Clinical Microbiology, 2004
- Dientamoeba fragilis, a neglected cause of diarrhea, successfully treated with secnidazoleClinical Microbiology and Infection, 2003
- Dientamoeba fragilis An unusual intestinal pathogenDigestive Diseases and Sciences, 1996